US Patent

US10143680 — Pharmaceutical dosage forms

Formulation · Assigned to Novartis AG · Expires 2035-07-06 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical dosage forms for oral administration that contain OSILODROSTAT PHOSPHATE or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.

Drugs covered by this patent

osilodrostat-phosphate (OSILODROSTAT PHOSPHATE)

Patent Metadata

Patent number: US10143680
Jurisdiction: US
Classification: Formulation
Expires: 2035-07-06
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.